IMMvention Therapeutix, Inc ., an early-stage biotechnology company focused on discovering and developing human therapeutics, today announced a strategic collaboration and license agreement with Novo ...

Poxel receives Chinese patent for use of Imeglimin for type-2 diabetic patients with renal impairment: Lyon, France Wednesday, January 22, 2025, 18:00 Hrs [IST] Poxel SA, a clinic ...

The role of the psychiatric mental health practitioner has evolved, yet one thing remains constant: the need for primary ...

A study published by researchers from the Sant Pau Research Institute (IR Sant Pau) and the Stroke Unit of Sant Pau Hospital ...

RS BioTherapeutics, whose mission is to develop life-changing medicines for the millions of people suffering from deadly lung diseases characterized by pulmonary inflammation, is pleased to announce ...

CGRP Inhibitors Market. The global CGRP inhibitors market is poised for robust growth, with its valuation expected to rise ...

The following is a summary of “Unmasking High-Output Heart Failure: Beyond Conventional Paradigms,” published in the January ...

Cystic fibrosis (CF) is a life-threatening genetic disease affecting multiple organ systems, with pancreatic dysfunction representing a critical and often overlooked complication.

Announcing a new article publication for Cardiovascular Innovations and Applications journal. Many studies have reported that obesity causes heart failure (HF) pathogenesis.

US-based biotechnology company Ocugen has dosed the first subject in a multicentre Phase I trial of OCU200 for diabetic ...

“We are enthusiastic about getting patients started in the OCU200 Phase 1 clinical trial and sharing not only safety but preliminary efficacy data as the study progresses,” said Dr. Huma Qamar, Chief ...

The Lancet Diabetes & Endocrinology published its Commission on the definition and diagnostic criteria of clinical obesity.